

EFW



July 6, 2006

Certificate of Mailing

Under 37 CFR 1.8(a) I certify that this correspondence is being deposited with the United States Postal Service in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date indicated below:


Sara Hare

July 6, 2006
Date of Deposit

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Application Serial No.: 10/613,788
METHOD OF LONG TERM TREATMENT OF GRAFT-VERSUS-HOST
DISEASE USING TOPICAL ACTIVE CORTICOSTEROIDS
Our Docket No.: 8105-009-US-CON


Dear Sir or Madam:

Enclosed please find the following documents related to the above-identified matter:


1. Response to Notice Regarding Power of Attorney (2 pages);
2. Copy of Executed Revocation and Appointment of Power of Attorney (1 page);
3. Copy of Executed Statement Under 37 CFR 3.73(b) (1 page); and
4. Self-Addressed, Stamped Postcard

The self-addressed, stamped postcard has been included for your convenience. After confirming receipt of these documents please return the postcard to us at your earliest convenience. Should you have any questions, please do not hesitate to contact me by phone at (858) 450-0099.

Sincerely yours,


David M. Kohn, J.D.
Reg. No. 53,150

Enclosure(s)



PATENT
10/613,788

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MCDONALD et al.	Examiner: OLSON, Eric
Serial No.: 10/613,788	Art Unit: 1623
Filed: July 3, 2003	Attorney Ref. 8105-009-US-CON No.:
Title: METHOD OF LONG TERM TREATMENT OF GRAFT-VERSUS-HOST DISEASE USING TOPICAL ACTIVE CORTICOSTEROIDS	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE REGARDING POWER OF ATTORNEY

Dear Sir:

In response to the Notice Regarding Power of Attorney mailed June 9, 2006, Applicant submits the following documents:

Enclosed are an executed Power of Attorney Form and Statement Under 37 CFR 3.73(b) Form. The Statement Under 37 CFR 3.73(b) states that Enteron Pharmaceuticals, Inc., which is a subsidiary of DOR Biopharma, Inc., is the assignee of the entire right, title, and interest of Application Serial No. 10/613,788 by virtue of an executed assignment recorded in the United States Patent and Trademark Office at Reel 011584, Frame 0434, which includes

the right to ownership of all divisional and continuation applications of the invention entitled "METHOD OF LONG TERM TREATMENT OF GRAFT-VERSUS-HOST DISEASE USING TOPICAL ACTIVE CORTICOSTEROIDS."


Application Serial No. 10/613,788 is a continuation of Application Serial No. 09/753,814 by McDonald, filed on January 3, 2001 for which an assignment has been recorded with the Office at Reel 011584, Frame 0434.

If there are any questions or comments, Applicant's attorney may be reached at the telephone number stated below.

Respectfully submitted,

Date: _____

July 6, 2006



David M. Kohn, J.D.
Registration No. 53,150
(858) 450-0099 ext 308

Catalyst Law Group, APC
9710 Scranton Rd.
Suite 170
San Diego, CA 92121
Tel.: (858) 450 0099
Fax.: (858) 450 9834



BEST AVAILABLE COPY

REVOCATION AND APPOINTMENT OF POWER OR ATTORNEY

DOR BioPharma, Inc., owner of the below-identified application, appoint as their attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and transact all business in the United States Patent and Trademark Office, all of the registered practitioners identified by Customer Number 32301:

CATALYST LAW GROUP, APC
9710 Scranton Rd.
Suite 170
San Diego, CA 92121

In regard to the following application:

Serial No.	Title	Filed	Status	Attorney Docket No.
11/320,564	Treatment of Graft-Versus-Host Disease and Leukemia with Beclomethasone Dipropionate and Prednisone	December 30, 2005	Pending	8105-012-US

DOR BioPharma, Inc.

Name: Robert N. Brey, Ph.D.
Title: Chief Scientific Officer

DATE: June 8, 2006



BEST AVAILABLE COPY

PTO/SB/96 (12-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: ENTERON Pharmaceuticals, Inc.

Application No./Patent No./Control No.: 10/613,788 Filed/Issue Date: July 3, 2003

Entitled: METHOD OF LONG TERM TREATMENT OF GRAFT-VERSUS-HOST DISEASE USING TOPICAL ACTIVE CORTICOSTEROIDS

ENTERON Pharmaceuticals, Inc.

(Name of Assignee)

a Corporation

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 011584, Frame 0434, or a true copy of the original assignment is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Robert N. Brey
Signature

Robert Brey, Ph.D.

Printed or Typed Name

Chief Scientific Officer
Title

July 6, 2006
Date

847 543 7725

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.